BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and ...
As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) ...
Inhibition of histone lysine demethylases with TACH101, a first-in-class pan-inhibitor of KDM4. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a ...
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
Second clinical candidate from HUTCHMED’s next-generation ATTC platform — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) ...
Kazia Therapeutics Ltd. raised AU$50 million (US$33.15 million) in a private placement of equity securities to advance lead candidate paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor in clinical ...
PI3K/AKT/mTOR pathway blockade with pan-PI3K/mTORC1/2 inhibition produced substantial PFS gains in PIK3CA wild-type disease, addressing an unmet need after CDK4/6 plus endocrine resistance. Adding ...
HOUSTON -- Two-thirds of patients with PI3K-mutant brain metastases responded to the maximum tolerated dose (MTD) of the small-molecule inhibitor paxalisib plus radiation therapy (RT), a small phase I ...
Hong Kong, Shanghai Friday, March 6, 2026, 10:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results